Adult treatment pathways
This summary follows NICE NG28, updated 18 February 2026, for adults aged 18 and over. Choose treatment around the person’s comorbidities, renal function and frailty. Pregnancy, children and acute DKA/HHS use their separate pathways.
Key points
- NG28 2026: offer modified-release metformin plus an SGLT-2 inhibitor initially for adults with no relevant comorbidity, or those with heart failure or obesity; renal impairment and frailty alter the pathway.
- Established ASCVD: offer modified-release metformin, an SGLT-2 inhibitor and subcutaneous semaglutide (Ozempic), up to 1 mg once weekly. If metformin cannot be used, retain the other two medicines.
- The SGLT-2 recommendation is not gated by QRISK3 ≥10%. QRISK3 still informs separate primary-prevention statin decisions.
- Initial HbA1c target: 48 mmol/mol (6.5%) without hypoglycaemia-causing medicines; 53 mmol/mol (7.0%) with them. Agree a less stringent target individually when appropriate.
- Introduce medicines sequentially and review benefit. Do not combine a DPP-4 inhibitor with a GLP-1 receptor agonist or tirzepatide.
- SGLT-2-associated DKA can occur with near-normal glucose. Acute vomiting, abdominal pain, rapid breathing, dehydration or impaired consciousness needs urgent assessment.
Overview and classification
Type 2 diabetes combines insulin resistance with progressive loss of beta-cell function. Treatment aims include reducing symptoms and microvascular harm, preventing cardiovascular and renal events, and preserving quality of life. Revisit the diagnosis when the presentation or treatment response suggests type 1 diabetes or another cause; weight or age alone cannot reliably classify diabetes. NICE defines early-onset type 2 diabetes as diagnosis before age 40; its adult recommendations apply from age 18.
Clinical Features
Symptoms
May be asymptomatic — often detected on routine blood tests or screening
Polyuria and polydipsia (osmotic diuresis from hyperglycaemia)
Fatigue
Blurred vision (glucose-related lens swelling)
Recurrent infections (UTI, candidiasis, skin infections)
Slow wound healing
Unintentional weight loss or rapid symptom onset — assess insulin deficiency and alternative diabetes type
Symptoms of complications at presentation (neuropathy, foot ulcer, visual loss)
Signs
Overweight or central adiposity may be present; type 2 diabetes also occurs at lower BMI
Acanthosis nigricans (velvety hyperpigmented skin in flexures — marker of insulin resistance)
Signs of complications: diabetic retinopathy on fundoscopy, peripheral neuropathy (reduced sensation), foot ulceration
Hypertension (frequently coexistent)
Investigations
First-line
HbA1c and fasting plasma glucoseHbA1c ≥48 mmol/mol (6.5%) or fasting plasma glucose ≥7.0 mmol/L indicates possible diabetes. Obtain a second blood test to confirm an asymptomatic result; assess symptomatic or acutely unwell people promptly rather than waiting for routine retesting.
Assess immediate risk and classificationCheck ketones and acute illness when indicated, especially with weight loss, vomiting, dehydration or SGLT-2 use. Investigate HbA1c/glucose discrepancies; abnormal haemoglobin or altered red-cell turnover can invalidate HbA1c.
Second-line
Lipid profileTotal cholesterol, HDL, LDL, triglycerides — dyslipidaemia is common
U&Es + eGFRBaseline renal function — important before starting metformin and SGLT2i
Urine ACRScreen for diabetic nephropathy — annually from diagnosis
Retinal screeningRefer at diagnosis; follow the screening programme’s risk-based interval, commonly every 1 or 2 years rather than annual screening for everyone.
Foot assessmentAnnual structured foot check — monofilament, pulses, deformity
Specialist
C-peptide + GAD/IA2 antibodiesIf diagnostic uncertainty (thin patient, young age, rapid insulin requirement) — distinguish T2DM from LADA/T1DM
Initial medicines: choose the relevant NG28 pathway
NICE NG28 §§1.9–1.21, updated 18 February 20261
Shared plan, education and sequencing
- Offer structured education, individualised nutrition and physical-activity support, and appropriate weight-management or remission services alongside medicines. Assess cardiovascular disease, kidney function and frailty before prescribing.
- When comorbidities coexist, agree priorities while preserving indicated cardiorenal protection and respecting contraindications and treatment burden.
- Introduce medicines one at a time: start metformin and check tolerability; start the SGLT-2 inhibitor as soon as metformin reaches its maximum tolerated dose; introduce a GLP-1 receptor agonist or tirzepatide, when indicated, once the SGLT-2 inhibitor is at its maximum tolerated dose.
2
No relevant comorbidity, heart failure, or living with obesity
- Offer modified-release metformin plus an SGLT-2 inhibitor. Heart-failure recommendations apply at any ejection fraction.
- If metformin is contraindicated or not tolerated, offer SGLT-2 inhibitor monotherapy. This is not restricted to a high QRISK3 score or failure of metformin alone.
3
Atherosclerotic cardiovascular disease (ASCVD)
- Offer modified-release metformin, an SGLT-2 inhibitor and subcutaneous semaglutide (Ozempic), up to 1 mg once weekly, for cardiovascular, renal and glycaemic benefits.
- If metformin is contraindicated or not tolerated, offer the SGLT-2 inhibitor plus subcutaneous semaglutide. If ASCVD develops after initial therapy, offer to add this semaglutide regimen.
4
Early-onset type 2 diabetes: diagnosed before age 40
- Offer modified-release metformin plus an SGLT-2 inhibitor; consider adding a GLP-1 receptor agonist for cardiovascular, renal and glycaemic benefits, or tirzepatide for glycaemic benefit.
- If metformin cannot be used, offer an SGLT-2 inhibitor and consider the same additional options.
5
Chronic kidney disease: use current eGFR
- eGFR ≥30 mL/min/1.73 m²: offer modified-release metformin plus an SGLT-2 inhibitor; if metformin cannot be used, offer the SGLT-2 inhibitor alone.
- eGFR ≥20 but <30: offer dapagliflozin or empagliflozin plus a DPP-4 inhibitor. Metformin is contraindicated below 30.
- eGFR <20: consider a DPP-4 inhibitor.
- If a DPP-4 inhibitor in the initial renal pathway is contraindicated, not tolerated or ineffective, consider pioglitazone or insulin. Check renal dosing and the selected medicine’s product information.
6
Frailty: balance benefit with adverse-event risk
- Offer modified-release metformin; add an SGLT-2 inhibitor only if the level of frailty does not create a risk of adverse events such as volume depletion or hypotension.
- If metformin cannot be used, consider SGLT-2 monotherapy when frailty-related adverse-event risk is acceptable; otherwise consider DPP-4 inhibitor monotherapy. Review for the smallest effective number of medicines at the lowest effective doses.
Further medicines and treatment review
NICE NG28 §§1.22–1.311
Optimise current treatment first
- Review adherence, adverse effects, doses, formulations and healthy living before adding treatment. Existing standard-release metformin may continue when still appropriate; switch to modified release if not tolerated or preferred.
- Consider continuing SGLT-2 inhibitors for cardiovascular or renal benefit even when their glucose-lowering effect is insufficient. Do not combine a DPP-4 inhibitor with a GLP-1 receptor agonist or tirzepatide.
2
Further glycaemic treatment by comorbidity
- No relevant comorbidity: offer a DPP-4 inhibitor; if unsuitable or ineffective, offer a sulfonylurea, pioglitazone or insulin. Heart failure: offer a DPP-4 inhibitor, then a sulfonylurea or insulin if needed; pioglitazone is contraindicated in heart failure.
- ASCVD requiring additional glycaemic treatment: offer a sulfonylurea, pioglitazone or insulin alongside current treatment, accounting for other contraindications.
- Early-onset diabetes: consider GLP-1 receptor agonist or tirzepatide if additional treatment is needed. Living with obesity: consider either only after at least 3 months of initial therapy, when further treatment is needed for the individualised glycaemic target and neither is already prescribed.
- For early-onset diabetes or obesity, offer a DPP-4 inhibitor if GLP-1/tirzepatide is unsuitable; if that is unsuitable or ineffective, or GLP-1/tirzepatide is already being taken and more treatment is needed, use a sulfonylurea, pioglitazone or insulin as appropriate.
- CKD or frailty: consider DPP-4 treatment first, then other suitable treatment if already taking it or it is unsuitable/ineffective. In CKD, consider a sulfonylurea only at eGFR ≥30; consider pioglitazone or insulin as alternatives. In frailty, account for hypoglycaemia and falls with sulfonylureas or insulin.
3
GLP-1 receptor agonists and tirzepatide: review the indication
- NG28’s 2026 GLP-1 class recommendations cover liraglutide, dulaglutide and semaglutide; its Ozempic recommendations cover doses up to 1 mg weekly. Weight-management prescribing follows the separate obesity guideline.
- Stop GLP-1/tirzepatide if BMI falls below 18.5 kg/m². Stop if it does not help the glycaemic target and is not being taken for cardiovascular benefit.
- Discuss pregnancy plans, effective contraception and product-specific washout periods. These medicines should not be taken during pregnancy, when trying to conceive or while breastfeeding. Tirzepatide users taking oral contraception need an additional barrier method or a non-oral contraceptive for 4 weeks after starting and each dose increase, following MHRA advice.
4
Insulin when indicated
- Symptomatic hyperglycaemia may need insulin or a sulfonylurea, followed by review once glucose is controlled; suspected DKA or HHS requires the separate emergency pathway.
- Offer initial basal insulin once or twice daily. Especially when HbA1c is ≥75 mmol/mol (9.0%), consider basal plus short/rapid-acting insulin, separately or as a premix. Choose the preparation with the person, considering support needs, hypoglycaemia and injection preference; use the least costly equally suitable option.
- Continue existing metformin when starting insulin. Stop other medicines used solely for hyperglycaemia, while discussing continuation for cardiovascular or weight benefits. Provide injection, titration, monitoring, hypoglycaemia and driving education with trained support.
Targets, monitoring and complication prevention
NICE NG28 blood glucose and complications; NG136, NG203 and NG2381
Agree an HbA1c target and monitoring plan
- Aim for 48 mmol/mol (6.5%) with healthy living and an initial regimen not associated with hypoglycaemia; aim for 53 mmol/mol (7.0%) with hypoglycaemia-causing medicines. These targets do not depend simply on monotherapy versus dual therapy.
- If HbA1c rises to ≥58 mmol/mol (7.5%) on the initial regimen, revisit healthy living and adherence, intensify medicines and aim for 53 mmol/mol. Relax targets individually for frailty, limited life expectancy, major comorbidity or unacceptable hypoglycaemia risk.
- Measure HbA1c every 3–6 months until stable on unchanged therapy, then every 6 months. Use appropriate alternatives or specialist advice when HbA1c is unreliable.
2
Glucose self-monitoring and CGM
- Do not routinely offer finger-prick testing to everyone: indications include insulin, hypoglycaemia, medicines creating driving/occupational hypoglycaemia risk, and pregnancy; short-term monitoring can help with corticosteroids or suspected hypoglycaemia.
- Offer isCGM with multiple daily insulin injections when recurrent/severe hypoglycaemia, impaired awareness, inability to finger-prick but ability to use isCGM, or a need for ≥8 tests daily applies. Also offer it when insulin-treated adults need a care worker or professional to monitor glucose. Consider rtCGM if available at the same or lower cost; retain finger-prick backup and education.
3
Kidneys, eyes, feet and oral health
- Review kidney function and urine ACR, foot risk, blood pressure, lipids, hypoglycaemia and treatment burden. Refer to retinal screening at diagnosis and follow risk-based screening invitations, commonly every 1 or 2 years.
- Discuss periodontal risk and regular dental review, neuropathy and relevant erectile dysfunction at annual review. Sudden visual loss, an acute diabetic foot problem or systemic illness needs urgent assessment.
4
Blood pressure and cardiovascular prevention
- For hypertension without CKD-specific targets, clinic BP targets are <140/90 mmHg below age 80 and <150/90 from age 80, with individual judgement for frailty. In CKD, use NG203 targets: <140/90 when ACR <70 mg/mmol and <130/80 when ACR ≥70. Check postural BP in type 2 diabetes; use standing BP when a significant postural drop or symptoms are present.
- For CKD with diabetes, offer an ACE inhibitor or ARB, titrated to the highest tolerated licensed dose, when ACR is ≥3 mg/mmol; monitor renal function and potassium appropriately.
- Use NG238 for lipid prevention: offer atorvastatin 20 mg for primary prevention at QRISK3 ≥10%; assess CKD and other indications separately. Established cardiovascular disease generally requires atorvastatin 80 mg, with a lower dose for interactions, high adverse-effect risk or preference. Do not prescribe aspirin or clopidogrel solely for diabetes in someone without cardiovascular disease.
5
Sick-day safety and acute illness
- Give an individual sick-day plan covering dehydration, vomiting/diarrhoea, surgery, medicine interruption and restarting. Assess and address DKA risks before SGLT-2 treatment, including previous DKA, acute illness and ketogenic diets.
- Interrupt SGLT-2 treatment during hospitalisation for major surgery or acute serious illness; monitor blood ketones and restart only when ketones are normal and the person is clinically stable. Acute DKA can be euglycaemic; use the emergency pathway rather than escalating routine oral treatment.
Complications and acute deterioration
Important complications include retinopathy, kidney disease, peripheral and autonomic neuropathy, foot ulceration, coronary disease, stroke and peripheral arterial disease. Severe dehydration, vomiting, abdominal pain, rapid breathing or altered consciousness requires urgent assessment for DKA/HHS or another acute illness. These emergencies can occur in type 2 diabetes; SGLT-2-associated DKA may have little glucose elevation. Their fluid, insulin and electrolyte treatment belongs to the separate acute-care pathways.
UKMLA Exam Tips
- 1NG28 2026 no-comorbidity starting regimen is modified-release metformin plus SGLT-2, introduced sequentially; QRISK3 ≥10% is not an eligibility gate for this regimen.
- 2ASCVD adds subcutaneous Ozempic up to 1 mg weekly. Early-onset diabetes and obesity have different GLP-1/tirzepatide indications; for obesity, assess glycaemic need after at least 3 months of initial therapy.
- 3Renal boundaries matter: eGFR ≥30, ≥20 but <30, and <20 have different initial regimens. Frailty adds an adverse-event assessment before SGLT-2 prescribing.
- 4HbA1c 48 versus 53 reflects hypoglycaemia risk and treatment stage, not simply the number of drugs; ≥58 on initial therapy prompts review and intensification.
- 5Avoid DPP-4 plus GLP-1/tirzepatide combinations. Pioglitazone is contraindicated in heart failure; sulfonylureas and insulin increase hypoglycaemia risk.
- 6Retinal screening is risk-based, not universally annual. SGLT-2-associated DKA may be euglycaemic; do not exclude an emergency because glucose is near normal.
Put your reading into practice
Checking available topic practice…
Choose UKMLA questions from the existing bank. General exam practice covers your selected topics; it is not filtered to this article. Your usual question-bank access applies.
Choose UKMLA practiceAfter your session, return to this section to revisit the reading and choose your next review.
regional clinical guidance
Type 2 Diabetes Mellitus: guidance by region
Recommendations, thresholds and pathways can differ. Open the page written for the jurisdiction you need.
Verified Sources & References
NICE NG28 — Initial medicines (18 February 2026 update)
NICE NG28 — Person-centred medicine and sick-day rules
NICE NG28 — How to introduce medicines
NICE NG28 — Further medication
NICE NG28 — Reviewing medicines
NICE NG28 — Blood glucose management
NICE NG28 — Insulin-based treatments
NICE NG28 — Complications
NICE NG28 — Terms, including early-onset diabetes
NICE PH38 — Confirmation of asymptomatic diagnostic tests
NICE NG136 — Blood pressure targets
NICE NG203 — CKD and blood pressure targets
NICE NG238 — Cardiovascular prevention
NHS — Risk-based diabetic eye screening
MHRA — SGLT-2 interruption and blood ketone monitoring
MHRA — GLP-1/tirzepatide safety, contraception and pregnancy
related resources
Save your place and choose what comes next
Endocrine & Metabolic · Article 1 of 25